Literature DB >> 17178865

RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.

Yu-Wen E Chang1, Jerry W Marlin, Terry W Chance, Rolf Jakobi.   

Abstract

Cyclooxygenase-2 (COX-2) represents an important target for treatment and prevention of colorectal cancer. Although COX-2 signaling is implicated in promoting tumor cell growth and invasion, the molecular mechanisms that mediate these processes are largely unknown. In this study, we show that the RhoA pathway mediates COX-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Disruption of adherens junctions promotes tumor cell invasion and metastasis and is often associated with tumor progression. We detected high levels of RhoA activity in HCA-7 colon carcinoma cells that constitutively express COX-2. Inhibition of COX-2 significantly reduced the levels of RhoA activity in HCA-7 cells, suggesting that constitutive expression of COX-2 stimulates RhoA activity. Interestingly, inhibition of COX-2 or silencing of COX-2 expression with small interfering RNA (siRNA) stimulated the formation of adherens junctions, concomitant with increased protein levels of E-cadherin and alpha-catenin. Furthermore, inhibition of RhoA or silencing of RhoA expression with siRNA increased the levels of E-cadherin and alpha-catenin. Inhibition of Rho kinases (ROCK), the RhoA effector proteins, also increased levels of E-cadherin and alpha-catenin and stimulated formation of adherens junctions. The motility of HCA-7 cells was significantly decreased when COX-2 or RhoA was inhibited. Therefore, our data reveal a novel molecular mechanism that links COX-2 signaling to disrupt the formation of adherens junctions; COX-2 stimulates the RhoA/ROCK pathway, which reduces levels of E-cadherin and alpha-catenin leading to disruption of adherens junction formation and increased motility. Understanding of COX-2 downstream signaling pathways that promote tumor progression is crucial for the development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178865     DOI: 10.1158/0008-5472.CAN-06-1818

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

2.  Specific upregulation of RHOA and RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer.

Authors:  Patricia Bortman Rozenchan; Fatima Solange Pasini; Rosimeire A Roela; Maria Lúcia Hirata Katayama; Fiorita Gonzáles Lopes Mundim; Helena Brentani; Eduardo C Lyra; Maria Mitzi Brentani
Journal:  Tumour Biol       Date:  2015-07-05

3.  Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.

Authors:  Tae Jung Jang; Woo Heon Cha; Kyung Seob Lee
Journal:  Virchows Arch       Date:  2010-06-26       Impact factor: 4.064

4.  Rho GEFs in endothelial junctions: Effector selectivity and signaling integration determine junctional response.

Authors:  Siu P Ngok; Panos Z Anastasiadis
Journal:  Tissue Barriers       Date:  2013-11-15

5.  miR-126: A novel regulator in colon cancer.

Authors:  Weina Huang; Jie Lin; Hongxuan Zhang
Journal:  Biomed Rep       Date:  2015-12-02

6.  MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway.

Authors:  Nan Li; Anliu Tang; Shuo Huang; Zeng Li; Xiayu Li; Shourong Shen; Jian Ma; Xiaoyan Wang
Journal:  Mol Cell Biochem       Date:  2013-04-25       Impact factor: 3.396

7.  Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells.

Authors:  S C Kirkland
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

8.  The bacterial virulence factor lymphostatin compromises intestinal epithelial barrier function by modulating rho GTPases.

Authors:  Brian A Babbin; Maiko Sasaki; Kirsten W Gerner-Schmidt; Asma Nusrat; Jan-Michael A Klapproth
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 9.  New insights into the aetiology of colorectal cancer from genome-wide association studies.

Authors:  Albert Tenesa; Malcolm G Dunlop
Journal:  Nat Rev Genet       Date:  2009-06       Impact factor: 53.242

10.  Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling.

Authors:  Suresh Guruswamy; Chinthalapally V Rao
Journal:  Gene Regul Syst Bio       Date:  2008-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.